Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.20.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Income Statement [Abstract]        
Product revenue $ 66 $ 173 $ 478 $ 437
Costs of revenue 53 151 382 364
Gross profit 13 22 96 73
Operating expenses:        
Research and development 1,432 869 3,494 2,557
General and administrative 827 714 2,418 2,166
Sales and marketing 182 139 450 303
Total operating expenses 2,441 1,722 6,362 5,026
Loss from operations (2,428) (1,700) (6,266) (4,953)
Other income (expenses):        
Interest expense (1) (1) (2) (3)
Interest income 78 111 267 349
Change in fair value of derivative liabilities (287) 144 1,750 754
Offering costs (1,246)
Other income, net 201 201 48
Total other income (expense), net (9) 254 970 1,148
Net loss before income taxes (2,437) (1,446) (5,296) (3,805)
Provision for income taxes
Net loss (2,437) (1,446) (5,296) (3,805)
Deemed dividend related to the beneficial conversion feature and accretion of a discount on series B preferred stock (74) (345) (9,565) (2,703)
Net loss attributable to common stockholders $ (2,511) $ (1,791) $ (14,861) $ (6,508)
Net loss per share - basic and diluted        
Basic - net loss $ (0.11) $ (0.68) $ (0.39) $ (3.00)
Basic - deemed dividend and accretion of a discount on conversion of preferred stock (0.16) (0.70) (2.13)
Basic - attributable to common stockholders (0.11) (0.84) (1.09) (5.13)
Diluted - net loss (0.11) (0.75) (0.49) (3.59)
Diluted - deemed dividend and accretion of a discount on conversion of preferred stock (0.16) (0.63) (2.13)
Diluted - attributable to common stockholders $ (0.11) $ (0.91) $ (1.12) $ (5.72)
Weighted average common shares outstanding:        
Basic 22,774,263 2,127,293 13,671,866 1,269,106
Diluted 22,774,263 2,127,293 15,094,276 1,269,106